About tal az opari b
PARP inhibitor anticancer medicine
Used for
- Treats certain advanced breast cancers with inherited BRCA mutations.
- Treats certain advanced prostate cancers with inherited BRCA mutations, sometimes with enzalutamide.
Usual adult dose
Usually 1 mg by mouth once daily; dose may be reduced for kidney problems or side effects.
Common side effects
- Low blood-cell counts, including anemia, low platelets, and low white cells
- Tiredness or weakness
- Nausea, vomiting, or reduced appetite
- Hair loss
Important warnings
- Can cause serious bone-marrow suppression; blood counts require monitoring.
- Rarely causes myelodysplastic syndrome or acute myeloid leukemia.
- May harm an unborn baby; effective contraception is required during treatment.
- Capsules must be swallowed whole; do not open or dissolve them.
Pregnancy
May cause fetal harm. Avoid pregnancy during treatment and for at least 7 months after the final dose.
Breastfeeding
Do not breastfeed during treatment or for at least 1 month after the final dose.
Interactions
- Strong P-glycoprotein inhibitors can increase talazoparib levels.
- P-glycoprotein inducers can lower talazoparib levels.
- Enzalutamide is used with talazoparib for some prostate cancers and can affect treatment risks.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.